Abstract
Most patients who receive enhanced external counterpulsation (EECP) have symptomatic coronary artery disease. These patients have either responded poorly to pharmacologic therapy or are poor candidates for revascularization procedures. Such patients receive a variety of consistent benefits from EECP treatment. As more is learned about EECP, patients once excluded from early clinical trials are now able to take advantage of EECP. Nevertheless, EECP is not suitable for some patients. It has a favorable adverse event profile for most patients undergoing the treatment. Medicare reimbursement coverage limitations remain an obstacle to having a broad cross‐section of patients benefit from EECP.
Keywords: angina pectoris, congestive heart failure, coronary artery bypass graft, coronary artery disease, enhanced external counterpulsation (EECP), International EECP Patient Registry, Medicare
Full Text
The Full Text of this article is available as a PDF (82.2 KB).
References
- 1. Lawson WE, Kennard ED, Holubkov R, Kelsey SR, Strobeck JE, Soran O, Feldman AM, for the IEPR Investigators : Benefit and safety of enhanced external counterpulsation in treating coronary artery disease patients with a history of congestive heart failure. Cardiology 2001; 96: 78–84 [DOI] [PubMed] [Google Scholar]
- 2. Wu GF, Zheng OS, Zheng ZS, Zhang MQ, Lawson WE, Hui JCK: A neurohormonal mechanism for the effectiveness of enhanced external counterpulsation (abstr 4390). Circulation 1999; 100 (suppl 1): I‐832 [Google Scholar]
- 3. Lawson WE, Hui JCK, Lang G: Treatment benefit in the enhanced external counterpulsation consortium. Cardiology 2000; 94: 31–35 [DOI] [PubMed] [Google Scholar]
- 4. Lawson WE, Kennard ED, Hui JCK, Holubkov R, Kelsey SF: Predictors of successful response to enhanced external counterpulsation as treatment of angina pectoris (abstr 3332). Circulation 2000; 102 (18): II–689 [Google Scholar]
- 5. Lawson WE, Hui JCK, Saroff HS, Zheng ZS, Kaydon DS, Sasvary D, Atkins H, Cohn PR: Efficacy of enhanced external counterpulsation in the treatment of angina pectoris. Am J Cardiol 1992; 70: 859–862 [DOI] [PubMed] [Google Scholar]
- 6. Lawson WE, Hui JCK: Enhanced external counterpulsation for chronic myocardial ischemia. J Crit Illness 2000; 15 (11): 629–636 [Google Scholar]
- 7. Lawson WE, Hui JC, Zheng ZS, Burger L, Jiang L, Lillis O, Soroff HS, Cohn PE: Can angiographic findings predict which coronary patients will benefit from enhanced external counterpulsation? Am J Cardiol 1996; 77 (12): 1107–1109 [DOI] [PubMed] [Google Scholar]
- 8. Lawson WE, Hui JC, Guo T, Burger L, Cohn PF: Prior revascularization increases the effectiveness of enhanced external counterpulsation. Clin Cardiol 1998; 21 (11): 841–844 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Zheng ZS, Li TM, Kambie H, Chen GH, Yu LQ, Cai SR, Zhan CY, Chen YC, Wo SX, Chen GW: Sequential external counterpulsation (SECP) in China. Transactions of the American Society for Artificial Internal Organs 1983; 29: 599–603 [PubMed] [Google Scholar]
- 10. Lawson WE, Hui JCK, Kennard ED, Holubkov R, Kelsey SF: Are the initial benefits of enhanced external counterpulsation sustained at one year? (abstr.) J Am Coll Cardiol 2001. (2); 37: 328A 11153761 [Google Scholar]
- 11. Fitzgerald CP, Kennard ED, Lawson WE: Primary utilization to improve myocardial perfusion with enhanced external counterpulsation revascularization (PUMPER). (abstr.) Heart 2001; 85 (1): 41 [Google Scholar]
- 12. Froschermaier SE, Werner D, Leike S, Schneider M, Waltenberger J, Daniel WG, Wirth NP: EECP as a new treatment modality for patients with erectile dysfunction. Urologia Internationalis 1998; 61: 168–171 [DOI] [PubMed] [Google Scholar]